SCHEMBL1707356

SCHEMBL1707356

[CH2]CCc1cc(C)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
NOS1 P29475 3/20 0.43
KDM4E B2RXH2 3/20 0.43
NOS2 P35228 2/20 0.43
MEN1 O00255 1/20 0.43
NOS3 P29474 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
HTR1A P08908 4/20 0.40
ADRA1D P25100 4/20 0.40
ADRA1A P35348 4/20 0.40
ADRA1B P35368 4/20 0.40
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1443623 0.83
Hydrochloric Acid SCHEMBL10858865 0.81 UHRF1 (0.48) UHRF1CCR1CCR5CCR8NOS1
SCHEMBL7893402 0.81 KDM4E (0.55) UHRF1CCR1CCR5CCR8NOS1
Hydrochloric Acid SCHEMBL11412762 0.81 UHRF1 (0.48) UHRF1CCR1CCR5CCR8NOS1
SCHEMBL6466772 0.79 UHRF1 (0.46) UHRF1CCR1CCR5CCR8NOS1
SCHEMBL701632 0.79 HRH1 (0.50) UHRF1CCR1CCR5CCR8NOS1
SCHEMBL27800512 0.79 UHRF1 (0.46) UHRF1CCR1CCR5CCR8NOS1
SCHEMBL31521647 0.79 HRH1 (0.50) UHRF1CCR1CCR5CCR8NOS1
SCHEMBL5712532 0.79 UHRF1 (0.42) UHRF1CCR1CCR5CCR8NOS1
SCHEMBL30932457 0.78 UHRF1 (0.54) UHRF1CCR1CCR5CCR8NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9126987-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-09-08 US disclosed
EP-2091948-B1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-04-18 EP disclosed
EP-2091948-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2009-08-26 EP disclosed
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-09-04 US disclosed
WO-2008065141-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, GLUL UHRF1 3884/4885CCR1 2884/4885CCR5 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.